"The Swiss drugmaker also defenestrated three phase 1 programs. Anti-CD25 Treg depleter RG6292 landed on the discard pile. Roche previously stopped a monotherapy clinical trial but continued to study RG6292 in combination with its checkpoint inhibitor Tecentriq."
#Immunology #Treg
https://www.fiercebiotech.com/biotech/roche-pumps-brakes-pompe-axing-gene-therapy-after-assessing-competition